Clinical Trials

Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

Inovio has secured approval from the US Food & Drug Administration (FDA) to begin phase 2 segment of its planned phase 2/3 clinical trial for its Covid-19 DNA vaccine candidate.

Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis

Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the first patient in the phase II idiopathic pulmonary fibrosis (IPF) study has been recruited in India.

AstraZeneca’s Calquence fails to meet primary efficacy endpoint in phase II Covid-19 trials

AstraZeneca announced that its Calquence (acalabrutinib) has failed to meet the primary efficacy endpoint in the CALAVI phase II trials, which evaluated patients hospitalised with respiratory symptoms of Covid-19.

Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment

Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of Covid-19 in high-risk outpatients and has begun enrolling patients.

Russia’s Sputnik V vaccine shows 92% efficacy in phase III Covid-19 trials

Russia’s National Research Centre for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) announced that their Sputnik V vaccine has demonstrated a significant effect against Covid-19 patients in phase III clinical trials.

Tezepelumab NAVIGATOR trial in severe, uncontrolled asthma patients meets primary endpoint

AstraZeneca and Amgen announced positive results from the NAVIGATOR Phase III trial for the potential new medicine tezepelumab in patients with severe, uncontrolled asthma

ViiV Healthcare says cabotegravir is superior to oral standard of care for HIV prevention in women

ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of the HIV Prevention Trials Network (HPTN) 084 study evaluating the safety and efficacy of investigational, long-acting, injectable cabotegravir for HIV prevention in women.

Pfizer and BioNTech’s Covid-19 vaccine candidate shows promising efficacy

Pfizer and BioNTech announced that their mRNA-based vaccine candidate has shown a significant effect against Covid-19 patients in the first interim efficacy analysis of phase 3 clinical trial.

Novartis’ canakinumab fails to meet primary endpoint in CAN-COVID trial

Novartis announced that its biologic medicine canakinumab has failed to achieve its primary endpoint in the phase III CAN-COVID trial.